Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neurofibromatosis 1 12Neurofibroma, Plexiform 6Carcinoma, Non-Small-Cell Lung 4Neurofibrosarcoma 3Neoplasms 3Lung Neoplasms 3Melanoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Gallbladder Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

vistusertib 1olaparib 1durvalumab 1danvatirsen 1adavosertib 1Neoadjuvant Therapy 1Cystectomy 1AZD4547 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Cancer × AZD 6244 × 1 year × Clear all
NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting
117 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡